SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~March~~January 2517, ~~2020~~2022

GREEN VISION BIOTECHNOLOGY CORP. (Exact name of registrant as specified in its charter)

GREEN VISION BIOTECHNOLOGY CORP.

Nevada	000-55210	98-1060941
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

Rooms 1804-06, 18/F., Wing On House,71 Des Voeux Road Central, ~~Hong Kong SAR, China (Address of registrant's principal executive offices)~~

Hong Kong SAR, China

(Address of registrant's principal executive offices)

+852-94929967

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging growth company ¨~~

IfEmerging ~~an emerging~~ growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ☐

~~Item~~If ~~8.01~~an ~~Other~~emerging ~~Events~~growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Green~~Item ~~Vision Biotechnology Corp~~5.01 ~~(the~~Changes “Company”) hereby announces that it is relying the order of the Securities and Exchange Commission, Release No. 34-88318, dated March 4, 2020 for the extension of the filing deadline of its Annual Report on Form 10-K, for the year ended December 31, 2019. There was an outbreak of Coronavirus in ~~China~~Control ~~at the end~~ of ~~January, 2020~~Registrant. In order to avoid the risk of the virus spreading, the Chinese government required enterprises to delay the resumption of work and production, this included City lockdown, travel suspension, operation suspension, 14-days quarantine, and the work from home. The Company has major operation in Jinzhong, Shanxi and abided by the government rule to suspend operation since late January 2020. This has hindered the progress of performing audit procedures so as to express an appropriate audit opinion for the audit of the Company. Because of the government order to suspend operation, the Company’s accounting staff could not access to the physical records of the Company which cause a delay in providing the relevant information to the Company’s independent public accountant so as to perform the required audit procedures.

~~The~~On ~~delay~~January to17, ~~provide~~2022, ~~responses~~as toa ~~auditor~~result ~~inquiries~~of ~~also~~a ~~effected~~private transactions, 75,674,200 shares of common stock, $0.001 par value per share (the ~~hardworking~~"Shares") of Green Vision Biotechnology Corp., a Nevada corporation (the "Company’s"), ~~management~~were ~~because~~transferred itfrom ~~took~~Leung ~~more~~Kwong ~~time~~Tak to ~~collect~~Well ~~the~~Supreme ~~appropriate~~International ~~information~~Limited (the “Purchaser”), ~~access~~through the sale of all of the issued and ~~locate~~outstanding ~~relevant~~shares ~~documents~~of common stock of Able Lead Holdings Limited, ~~and~~the ~~re-arrange~~former ~~various~~holder ~~resources~~of the Shares. ~~The~~William ~~aforementioned~~Ching ~~and~~Wan Lam is the ~~subsequent~~owner ~~delays~~of ~~relating~~the toPurchaser. As a result, the ~~completion~~Purchaser, and William Ching Wan Lam, the Company’s Chief Executive Officer and a Director, through his control of ~~audit~~the ~~procedures~~Purchaser ~~have~~became ~~caused~~a holder of approximately 50.796% of the ~~filing~~voting rights of the ~~Form~~issued ~~10-K~~and outstanding share capital of the Company on ora ~~before~~fully-diluted ~~April~~basis 15of the Company, ~~2020~~and tobecame ~~become~~the ~~impossible~~controlling shareholder. The ~~Company~~consideration ~~expects~~paid tofor ~~file~~the Shares was $227,023. The source of the ~~annual~~cash ~~report~~consideration onfor ~~Form~~the ~~10-K~~Shares onwas ~~May~~personal ~~15,~~funds ~~2020~~of the Purchaser.

There are no arrangements or understandings among both the former and new control persons and their associates with respect to the election of directors of the Company or other matters.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 ~~Letter~~SUMMARY ~~from~~OF ~~the~~STOCK ~~Company’s~~PURCHASE ~~independent~~AGREEMENT, ~~public~~dated ~~accountant.~~December 2, 2021, by and between Well Supreme International Limited and Leung Kwong Tak

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GREEN VISION BIOTECHNOLOGY CORP.
Dated: March 27, 2020	By:	/s/ William Ching Wan Lam
		William Ching Wan Lam, Chief Executive Officer

GREEN VISION BIOTECHNOLOGY CORP.

Dated: January 19, 2022

/s/ William Ching Wan Lam
By: William Ching Wan Lam, Chief Executive Officer

Filing Compare · GREEN VISION BIOTECHNOLOGY CORP.